Literature DB >> 26003814

Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.

Lifeng Lao1, Jeremiah R Cohen2, Elizabeth L Lord2, Zorica Buser3, Jeffrey C Wang4.   

Abstract

PURPOSE: A retrospective database review was carried out to evaluate the trends and demographics of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.
METHODS: Patients who underwent single-level PLF from 2005 to 2011 were identified by searching ICD-9 diagnosis and procedure codes in the PearlDiver Patient Records Database (PearlDiver Technologies, Fort Wayne, IN, USA), a national database of orthopaedic insurance records. The year of procedure, age, gender, and region of the United States were recorded for each patient. Results were reported for each variable as the incidence of procedures identified per 100,000 patients searched in the database.
RESULTS: Totally 5158 patients had single-level PLF in this study. The average rate of single-level PLF with rhBMP utilization maintained at a relatively stable level (19.1-23.5%) from 2005 to 2009, but sharply decreased to 6.8% in 2010 and 6.9% in 2011. The overall incidence of single-level PLF without rhBMP (1.37 cases per 100,000 patients) was more than five times of the incidence of single-level PLF with rhBMP (0.27 cases per 100,000 patients) (P < 0.01). The average rate of single-level PLF with rhBMP utilization is highest in Midwest (18.7%), followed by West (18.4%), South (16.4%) and Northeast (11.5%). The highest incidence of single-level PLF with rhBMP was observed in the group aged 70-74 years with an incidence of 0.33 per 100,000 patients.
CONCLUSIONS: The incidence of rhBMP utilization in single-level PLF increased from 2006 to 2009, but dropped to a low level in 2010 and 2011. The Northeast region had the lowest incidence of rhBMP utilization. The group aged 70-74 years trended to have the higher incidence of single-level PLF with rhBMP utilization.

Entities:  

Keywords:  Demographics; Posterior lumbar fusion; Recombinant human bone morphogenetic protein (rhBMP); Single-level

Mesh:

Substances:

Year:  2015        PMID: 26003814     DOI: 10.1007/s00586-015-4032-9

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  30 in total

1.  The efficacy of rhBMP-2 versus autograft for posterolateral lumbar spine fusion in elderly patients.

Authors:  Kwang-Bok Lee; Cyrus E Taghavi; Margaret S Hsu; Kyung-Jin Song; Jeong Hyun Yoo; Gun Keorochana; Stephanie S Ngo; Jeffrey C Wang
Journal:  Eur Spine J       Date:  2009-12-30       Impact factor: 3.134

2.  A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research.

Authors:  Eugene J Carragee; Ray M Baker; Edward C Benzel; Stanley J Bigos; Ivan Cheng; Terry P Corbin; Richard A Deyo; Eric L Hurwitz; Jeffrey G Jarvik; James D Kang; Jon D Lurie; Thomas E Mroz; F Cumhur Oner; Wilco C Peul; James Rainville; John K Ratliff; Jeffrey A Rihn; David J Rothman; Mark L Schoene; Dan M Spengler; Bradley K Weiner
Journal:  Spine J       Date:  2012-10       Impact factor: 4.166

3.  Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.

Authors:  Eugene J Carragee; Gilbert Chu; Rajat Rohatgi; Eric L Hurwitz; Bradley K Weiner; S Tim Yoon; Garet Comer; Branko Kopjar
Journal:  J Bone Joint Surg Am       Date:  2013-09-04       Impact factor: 5.284

4.  Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases.

Authors:  Steven D Glassman; Jennifer Howard; John Dimar; Alexander Sweet; Greg Wilson; Leah Carreon
Journal:  Spine (Phila Pa 1976)       Date:  2011-10-15       Impact factor: 3.468

5.  Administration of human recombinant bone morphogenetic protein-2 for spine fusion may be associated with transient postoperative renal insufficiency.

Authors:  Jonathan M Latzman; Li Kong; Chuanju Liu; Uzma Samadani
Journal:  Spine (Phila Pa 1976)       Date:  2010-04-01       Impact factor: 3.468

6.  Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011.

Authors:  Kern Singh; Sreeharsha V Nandyala; Alejandro Marquez-Lara; Steven J Fineberg
Journal:  Spine (Phila Pa 1976)       Date:  2014-03-15       Impact factor: 3.468

7.  Impact of bone morphogenetic proteins on frequency of revision surgery, use of autograft bone, and total hospital charges in surgery for lumbar degenerative disease: review of the Nationwide Inpatient Sample from 2002 to 2008.

Authors:  Phillip R Dagostino; Robert G Whitmore; Gabriel A Smith; Mitchell G Maltenfort; John K Ratliff
Journal:  Spine J       Date:  2012-12-05       Impact factor: 4.166

8.  Clinical outcomes in older patients after posterolateral lumbar fusion.

Authors:  Steven D Glassman; Leah Y Carreon; John R Dimar; Mitchell J Campbell; Rolando M Puno; John R Johnson
Journal:  Spine J       Date:  2007-01-09       Impact factor: 4.166

9.  Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2).

Authors:  Gregory S Cooper; Tzuyung Doug Kou
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-01       Impact factor: 3.468

10.  Recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in posterolateral lumbar spine fusion: complications in the elderly.

Authors:  Martin F Hoffmann; Clifford B Jones; Debra L Sietsema
Journal:  J Orthop Surg Res       Date:  2013-01-14       Impact factor: 2.359

View more
  4 in total

1.  Comparison of a calcium phosphate bone substitute with recombinant human bone morphogenetic protein-2: a prospective study of fusion rates, clinical outcomes and complications with 24-month follow-up.

Authors:  Rhiannon M Parker; Gregory M Malham
Journal:  Eur Spine J       Date:  2016-12-27       Impact factor: 3.134

Review 2.  Trends, Costs, and Complications of Anterior Cervical Discectomy and Fusion With and Without Bone Morphogenetic Protein in the United States Medicare Population.

Authors:  Elizabeth L Lord; Jeremiah R Cohen; Zorica Buser; Hans-Joerg Meisel; Darrel S Brodke; S Tim Yoon; Jim A Youssef; Jeffrey C Wang; Jong-Beom Park
Journal:  Global Spine J       Date:  2017-08-17

3.  Trends Analysis of rhBMP Utilization in Single-Level Posterior Lumbar Interbody Fusion in the United States.

Authors:  Lifeng Lao; Jeremiah R Cohen; Zorica Buser; Darrel S Brodke; Jim A Youssef; Jong-Beom Park; S Tim Yoon; Jeffrey C Wang; Hans-Joerg Meisel
Journal:  Global Spine J       Date:  2017-06-30

4.  A large database study of hospitalization charges and follow-up re-admissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2).

Authors:  Bradley Wetzell; Julie B McLean; Mark A Moore; Venkateswarlu Kondragunta; Kimberly Dorsch
Journal:  J Orthop Surg Res       Date:  2020-11-19       Impact factor: 2.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.